IPP Bureau

Granules India received ANDA approval for Metoprolol Succinate ER Tablets
Granules India received ANDA approval for Metoprolol Succinate ER Tablets

By IPP Bureau - June 14, 2023

Metoprolol Succinate ER Tablets are indicated for the treatment of hypertension in order to lower blood pressure.

Ampath expands its footprint in Andhra Pradesh
Ampath expands its footprint in Andhra Pradesh

By IPP Bureau - June 14, 2023

Launched Pathology Laboratory in Vijayawada offering a wide range of best-in-class diagnostic services with over 2500+ tests

Samsung Biologics and Pfizer collaborate for long-term manufacturing of biosimilars portfolio
Samsung Biologics and Pfizer collaborate for long-term manufacturing of biosimilars portfolio

By IPP Bureau - June 14, 2023

Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio

Merck gets favourable verdict in patent infringement lawsuit related to Bridion
Merck gets favourable verdict in patent infringement lawsuit related to Bridion

By IPP Bureau - June 14, 2023

Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.

Pfizer and GSK to battle for share of new RSV vaccine market, says GlobalData
Pfizer and GSK to battle for share of new RSV vaccine market, says GlobalData

By IPP Bureau - June 13, 2023

Pfizer is likely to show GSK significant competition

InnoCan submits new patent applications for advanced pain relief technology
InnoCan submits new patent applications for advanced pain relief technology

By IPP Bureau - June 13, 2023

The application is in line with Innocan's strategy to expand the scope of its combined magnesium and cannabis topical solution

Croma-Pharma enrolls first patient in hyaluronic acid dermal filler clinical trial in China
Croma-Pharma enrolls first patient in hyaluronic acid dermal filler clinical trial in China

By IPP Bureau - June 13, 2023

The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development

Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule
Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule

By IPP Bureau - June 13, 2023

UTD2 is the world's first oral epothilone microtubule inhibitor

Astellas submits new drug application for Zolbetuximab in Japan
Astellas submits new drug application for Zolbetuximab in Japan

By IPP Bureau - June 13, 2023

Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers

Solvay to build a multipurpose microbiology lab in Europe
Solvay to build a multipurpose microbiology lab in Europe

By IPP Bureau - June 13, 2023

The new lab will enable the Group to accelerate its efforts in this area, building new competencies and capabilities, as well as strengthening Solvay’s ability to develop breakthroughs in biodegradable-by-design solutions.

GSK receives USFDA file acceptance for Jemperli plus chemotherapy for the treatment of endometrial cancer
GSK receives USFDA file acceptance for Jemperli plus chemotherapy for the treatment of endometrial cancer

By IPP Bureau - June 12, 2023

Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities

Novartis unveils results of survey on chronic myeloid leukemia
Novartis unveils results of survey on chronic myeloid leukemia

By IPP Bureau - June 12, 2023

Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy

Novartis to acquire Chinook Therapeutics for US$ 3.2 bn
Novartis to acquire Chinook Therapeutics for US$ 3.2 bn

By IPP Bureau - June 12, 2023

Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease

Milla receives first cycle FDA approval for Dexmedetomidine Hydrochloride Injection
Milla receives first cycle FDA approval for Dexmedetomidine Hydrochloride Injection

By IPP Bureau - June 12, 2023

Mandaviya inaugurates CGHS Wellness Centres in Chandigarh and Panchkula
Mandaviya inaugurates CGHS Wellness Centres in Chandigarh and Panchkula

By IPP Bureau - June 12, 2023

Coverage of CGHS cities has expanded from 25 cities in 2014 to 80 in 2023

Latest Stories

Interviews

Packaging